MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ
3.000
+0.090
+3.09%
Opening 15:42 07/26 EDT
OPEN
2.990
PREV CLOSE
2.910
HIGH
3.049
LOW
2.860
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
5.78
52 WEEK LOW
2.010
MARKET CAP
626.35M
P/E (TTM)
-2.3414
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALLO last week (0715-0719)?
Weekly Report · 4d ago
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
A revolutionary cell-based gene therapy is showing promise for treating autoimmune diseases. Professor Georg Schett used CAR-T cell therapy for autoimmune conditions like lupus. The therapy is typically used for blood cancers, but has potential to be used for other diseases. The broader application of CAR-t faces challenges, including high costs and complex manufacturing processes.
Benzinga · 07/19 17:45
Allogene Therapeutics Currently Up Eight Consecutive Days, on Track for Longest Winning Streak Since April 2020 -- Data Talk
Dow Jones · 07/16 15:28
Allogene Therapeutics (ALLO) Gets a Buy from Piper Sandler
TipRanks · 07/16 12:16
Weekly Report: what happened at ALLO last week (0708-0712)?
Weekly Report · 07/15 09:09
Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline
Sana Biotechnology is a biotech company focused on developing engineered allogeneic cells for diseases with unmet clinical needs. Sana's most advanced product candidates leverage CRISPR technology to modify cells. The company's pipeline includes oncology, autoimmune disease, and regenerative medicine product candidates. Sana Biotechnology has a promising CAR-T Pipeline with positive pre-clinical results and first in-human trials starting in late 2023.
Seeking Alpha · 07/14 14:23
Weekly Report: what happened at ALLO last week (0701-0705)?
Weekly Report · 07/08 09:09
Caribou's Allogeneic CAR-T Therapy: Analyzing HLA Matching And CB-010's Clinical Performance
Caribou Biosciences, Inc. Experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. The CAR-T cell therapy showed limited efficacy in treating relapsed/refractory non-Hodgkin's lymphoma. The company has a "strong sell" rating for the stock.
Seeking Alpha · 07/05 19:18
More
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Webull offers Allogene Therapeutics Inc stock information, including NASDAQ: ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.